Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.23M 3.95M 3.62M 6.81M 465M 6.92M 46.3M 18.17M 233M 18.35M 17.94M 770M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.07M 10.34M 9.48M 17.84M 1.22B 18.12M 121M 47.61M 611M 48.06M 47.01M 2.02B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/04/20	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/04/20	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/03/20	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/03/20	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/03/20	Bidding Procedure Approved for Aradigm Corporation	CI
21/02/20	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/02/20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/11/19	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/10/19	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/10/19	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/07/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

16/06/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/06/20	ARADIGM CORP : Other Events (form 8-K)	AQ
01/05/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/04/20	ARADIGM CORP : Other Events (form 8-K)	AQ
06/04/20	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	48.7B
REVOLUTION MEDICINES, INC.	+3.51%	+8.31%	+481.14%	+585.26%	42.05B
IQVIA HOLDINGS INC.	+2.22%	+0.69%	+32.24%	+7.91%	38.26B
BEONE MEDICINES AG	+5.47%	+9.56%	+16.06%	+84.63%	37.5B
CELLTRION, INC.	+2.21%	+4.89%	+17.24%	+51.64%	31.44B
ASCENDIS PHARMA A/S	+2.74%	+4.80%	-	-	16.47B
MEDPACE HOLDINGS, INC.	+0.32%	+1.12%	+36.10%	+124.12%	16.33B
EUROFINS SCIENTIFIC SE	-0.11%	+1.75%	+8.05%	+18.47%	13.98B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.34%	+13.40%	+76.03%	+28.44%	12.68B
Average	+2.01%	+3.06%	+83.87%	+114.65%	28.6B
Weighted average by Cap.	+2.44%	+2.31%	+101.59%	+137.68%

Aradigm Corporation Stock OTC Bulletin Board

Stocks

ARDM

US0385053014

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

	2016	2017
Net sales	195K 169K 158K 144K 272K 18.56M 276K 1.85M 725K 9.3M 732K 716K 30.75M	14.46M 12.51M 11.68M 10.72M 20.16M 1.38B 20.48M 137M 53.81M 690M 54.32M 53.13M 2.28B
Net income	-32.94M -28.49M -26.61M -24.41M -45.91M -3.13B -46.64M -312M -123M -1.57B -124M -121M -5.19B	-10.7M -9.26M -8.65M -7.93M -14.92M -1.02B -15.16M -101M -39.82M -511M -40.2M -39.32M -1.69B
Net Debt	-9.37M -8.11M -7.57M -6.94M -13.06M -892M -13.27M -88.82M -34.86M -447M -35.19M -34.42M -1.48B	7.91M 6.84M 6.39M 5.86M 11.03M 753M 11.2M 74.99M 29.43M 377M 29.71M 29.06M 1.25B